H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on ABEO stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors including the promising outlook for Abeona Therapeutics’ product, ZEVASKYN, despite a slower than expected rollout. The product, approved for treating recessive dystrophic epidermolysis bullosa (RDEB), faced initial setbacks due to a false positive result in a sterility assay, but the company has since optimized the process and resumed operations, expecting commercial treatments to commence shortly.
Additionally, the market access and reimbursement landscape for ZEVASKYN appears favorable, with positive coverage established by major insurers and a permanent HCPCS J-code effective from January 2026. Although the company missed revenue expectations for 3Q25 due to no patient treatments, the financial outlook remains positive with anticipated revenue growth and a strong cash position expected to support operations for over two years.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 23.3% and a 51.40% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and Genmab.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $19.00 price target.